Skip to main content
OpenTrials

Clinical trial condition

Relapsing Remitting Multiple Sclerosis

Explore clinical trials studying Relapsing Remitting Multiple Sclerosis. Study availability and eligibility vary by location and protocol.

84 public trials 6 recruiting studies
Refine in advanced search Browse all conditions

Relapsing Remitting Multiple Sclerosis trial results

Completed

An Extension of the TG1101-RMS201 Trial

NCT03381170

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +6 more
Locations
  • TG Therapeutics Investigational Trial Site Pasadena, California, United States
  • TG Therapeutics Investigational Trial Site Aurora, Colorado, United States
  • TG Therapeutics Investigational Trial Site Lexington, Kentucky, United States
  • TG Therapeutics Investigational Trial Site Columbus, Ohio, United States
View Trial Details
Completed

Vitamin D Supplementation in Multiple Sclerosis

NCT01490502

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +6 more
Locations
  • Dignity Health Medical Foundation Carmichael, California, United States
  • University of California, San Francisco San Francisco, California, United States
  • Stanford University Stanford, California, United States
  • Yale University New Haven, Connecticut, United States
View all 16 locations
View Trial Details
Completed

Phase IIIB-IV Long-Term Follow-up Study for Patients Who Participated in CAMMS03409

NCT02255656

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +6 more
Locations
  • Investigational Site Number 1086 Cullman, Alabama, United States
  • Investigational Site Number 1031 Phoenix, Arizona, United States
  • Investigational Site Number 1171 Phoenix, Arizona, United States
  • Investigational Site Number 1090 Tucson, Arizona, United States
View all 131 locations
View Trial Details
Completed

A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo

NCT01067521

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +6 more
Locations
  • Teva Investigational Site 1332 Birmingham, Alabama, United States
  • Teva Investigational Site 1327 Gilbert, Arizona, United States
  • Teva Investigational Site 1311 Phoenix, Arizona, United States
  • Teva Investigational Site 1326 Fullerton, California, United States
View all 176 locations
View Trial Details

Related conditions